Laverock Therapeutics
Overview
Laverock Therapeutics is a biotech company specializing in gene-silencing technology aimed at developing programmable, advanced therapies to tackle significant diseases. The company was established in 2021 and is based in Stevenage, UK. It focuses on utilising Gene Editing induced Gene Silencing (GEiGS) technology for therapeutic purposes. David Venables, an experienced leader in biotech ventures, serves as the CEO. As of 2025, Laverock has raised over €23.3 million through seed funding, with significant contributions from investors such as Calculus Capital.
Recent Developments
-
June 2025: Laverock raised over €23.3 million in an expanded Seed funding round. The investment was led by Calculus Capital, with contributions from Eli Lilly, Mercia Ventures, and new investors like Norcliffe Capital. This round was focused on continuing technology validation and expanding partnerships.
-
April 2025: Laverock Theraupetics moved to the Apex Building within London Bioscience Innovation Centre in King's Cross, London. This strategic relocation supports the company's growth needs and continues its expansion within a state-of-the-art bioscience infrastructure.
-
March 2025: The company was officially welcomed to the newly completed facility at Tribeca London, with substantial lab space to aid in research and development.
-
September 2024: Significant advancements were announced in Laverock's GEiGS platform, which demonstrated programmable and stable gene silencing across multiple targets and cell types, underpinning future therapeutic expansions.
-
2023-2024: The company continued to focus on industrialization and validation of its technology platform, holding several presentations at key conferences including the European Society of Gene & Cell Therapy.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | Stevenage, UK |
| Founders | David Venables |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Calculus Capital, Eli Lilly, Mercia Ventures, Maven Capital |
| Industry | Biotechnology, HealthTech |
| Number of Employees | Approximately 24 as of 2024 |
| Subsidiaries | None noted |
Early History
Laverock Therapeutics was founded in 2021 to advance a unique platform known as Gene Editing induced Gene Silencing (GEiGS) targeted at human therapeutic applications. Its mission centers around engineering induced pluripotent stem cell (iPSC) derived therapies with better efficacy and safety. Early funding enabled the establishment of a dedicated laboratory in the Stevenage Bioscience Catalyst, hiring an expert team to advance development. The company emerged from its initial stealth phase to demonstrate the potential of its GEiGS technology, notably translating it from plant to human applications.
Company Profile and Achievements
Laverock Therapeutics employs a biotech model focused on developing programmable, tunable, and stable gene silencing therapies. Its proprietary GEiGS platform offers a paradigm shift in RNAi technology by allowing precise gene control, thereby facilitating novel therapeutic approaches. Key achievements include:
- 2021: Successful demonstration of the platform’s ability to target multiple genes simultaneously with specific silencing, paving the way for applications in oncology and genetic diseases.
- 2023-Present: Significant seed funding rounds exceeded £22.9M, positioning the company well for future R&D activities.
- Partnerships and Collaborations: Directed towards broadening therapeutic impact and exploring partnerships for diverse applications such as regenerative medicine and oncology.
Current Operations and Market Position
As of 2025, Laverock Therapeutics remains at the forefront of gene-silencing innovation, targeting key therapeutic areas like oncology and regenerative medicine. Its platform technology continues to receive validation for its unique attributes, enhancing its market position. The strategic location within London Bioscience Innovation Centre's state-of-the-art lab space enables it to collaborate efficiently with academic and industrial partners. Laverock stands poised to advance its lead candidates into preclinical development, illustrating a strong commitment to developing advanced therapies.
Conclusion
Laverock Therapeutics has positioned itself as an innovative leader in the gene-silencing biotech sector. Through its focused development of programmable advanced therapies, Laverock is set to influence the future of therapeutic strategies significantly. With continuous technological validation, robust funding, and strategic partnerships, the company is expected to make significant contributions to transforming treatment strategies for complex diseases, enhancing global health outcomes.